ニュース/Reuters/Merus’ Petosemtamab With Pembrolizumab Interim Data Demonstrates Robust Efficacy And Durability In 1L Pd-L1+ R/M HnsccMerus’ Petosemtamab With Pembrolizumab Interim Data Demonstrates Robust Efficacy And Durability In 1L Pd-L1+ R/M HnsccRefinitiv1分未満で読めますMRUSMerus NV MRUS:MERUS’ PETOSEMTAMAB WITH PEMBROLIZUMAB INTERIM DATA DEMONSTRATES ROBUST EFFICACY AND DURABILITY IN 1L PD-L1+ R/M HNSCCReuters欧州© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html詳細を表示ログイン、もしくは永年無料のアカウントを作成して、このニュースを読みましょう始めましょう
